Comparison of clinical outcome between surgical treatment and particle beam therapy for pelvic bone sarcomas: A retrospective multicenter study in Japan.

Clinical outcome Particle beam therapy Pelvic bone sarcoma Surgery

Journal

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
ISSN: 1436-2023
Titre abrégé: J Orthop Sci
Pays: Japan
ID NLM: 9604934

Informations de publication

Date de publication:
03 Jul 2024
Historique:
received: 03 04 2024
revised: 03 06 2024
accepted: 10 06 2024
medline: 5 7 2024
pubmed: 5 7 2024
entrez: 4 7 2024
Statut: aheadofprint

Résumé

Few studies have compared the clinical outcomes of patients with pelvic bone sarcomas treated surgically and those treated with particle beam therapy. This is a multicenter retrospective cohort study which compared the clinical outcomes of patients with pelvic bone sarcoma who underwent surgical treatment and particle beam therapy in Japan. A total of 116 patients with pelvic bone sarcoma treated at 19 specialized sarcoma centers in Japan were included in this study. Fifty-seven patients underwent surgery (surgery group), and 59 patients underwent particle beam therapy (particle beam group; carbon-ion radiotherapy: 55 patients, proton: four patients). The median age at primary tumor diagnosis was 52 years in the surgery group and 66 years in the particle beam group (P < 0.001), and the median tumor size was 9 cm in the surgery group and 8 cm in the particle beam group (P = 0.091). Overall survival (OS), local control (LC), and metastasis-free survival (MFS) rates were evaluated using the Kaplan-Meier method and compared among 116 patients with bone sarcoma (surgery group, 57 patients; particle beam group, 59 patients). After propensity score matching, the 3-year OS, LC, and MFS rates were 82.9% (95% confidence interval [CI], 60.5-93.2%), 66.0% (95% CI, 43.3-81.3%), and 78.4% (95% CI, 55.5-90.5%), respectively, in the surgery group and 64.9% (95% CI, 41.7-80.8%), 86.4% (95% CI, 63.3-95.4%), and 62.6% (95% CI, 38.5-79.4%), respectively, in the particle beam group. In chordoma patients, only surgery was significantly correlated with worse LC in the univariate analysis. The groups had no significant differences in the OS, LC, and MFS rates. Among the patients with chordomas, the 3-year LC rate in the particle beam group was significantly higher than in the surgery group.

Sections du résumé

BACKGROUND BACKGROUND
Few studies have compared the clinical outcomes of patients with pelvic bone sarcomas treated surgically and those treated with particle beam therapy. This is a multicenter retrospective cohort study which compared the clinical outcomes of patients with pelvic bone sarcoma who underwent surgical treatment and particle beam therapy in Japan.
METHODS METHODS
A total of 116 patients with pelvic bone sarcoma treated at 19 specialized sarcoma centers in Japan were included in this study. Fifty-seven patients underwent surgery (surgery group), and 59 patients underwent particle beam therapy (particle beam group; carbon-ion radiotherapy: 55 patients, proton: four patients).
RESULTS RESULTS
The median age at primary tumor diagnosis was 52 years in the surgery group and 66 years in the particle beam group (P < 0.001), and the median tumor size was 9 cm in the surgery group and 8 cm in the particle beam group (P = 0.091). Overall survival (OS), local control (LC), and metastasis-free survival (MFS) rates were evaluated using the Kaplan-Meier method and compared among 116 patients with bone sarcoma (surgery group, 57 patients; particle beam group, 59 patients). After propensity score matching, the 3-year OS, LC, and MFS rates were 82.9% (95% confidence interval [CI], 60.5-93.2%), 66.0% (95% CI, 43.3-81.3%), and 78.4% (95% CI, 55.5-90.5%), respectively, in the surgery group and 64.9% (95% CI, 41.7-80.8%), 86.4% (95% CI, 63.3-95.4%), and 62.6% (95% CI, 38.5-79.4%), respectively, in the particle beam group. In chordoma patients, only surgery was significantly correlated with worse LC in the univariate analysis.
CONCLUSIONS CONCLUSIONS
The groups had no significant differences in the OS, LC, and MFS rates. Among the patients with chordomas, the 3-year LC rate in the particle beam group was significantly higher than in the surgery group.

Identifiants

DOI: 10.1016/j.jos.2024.06.007 PMID: 38964957
pubmed: 38964957
pii: S0949-2658(24)00108-8
doi: 10.1016/j.jos.2024.06.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Toshiyuki Takemori (T)

Department of Orthopaedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-8558, Japan.

Hitomi Hara (H)

Department of Orthopaedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan. Electronic address: mitohi@med.kobe-u.ac.jp.

Teruya Kawamoto (T)

Department of Orthopaedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; Division of Orthopaedic Surgery, Kobe University Hospital, International Clinical Cancer Research Center, Kobe 650-0047, Japan.

Naomasa Fukase (N)

Department of Orthopaedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.

Ryoko Sawada (R)

Department of Orthopaedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.

Shuichi Fujiwara (S)

Department of Orthopaedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.

Ikuo Fujita (I)

Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-8558, Japan.

Takuya Fujimoto (T)

Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-8558, Japan.

Masayuki Morishita (M)

Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-8558, Japan.

Shunsuke Yahiro (S)

Department of Orthopaedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.

Tomohiro Miyamoto (T)

Department of Orthopaedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.

Masanori Saito (M)

Department of Orthopaedic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

Jun Sugaya (J)

Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.

Katsuhiro Hayashi (K)

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-8641, Japan.

Hiroyuki Kawashima (H)

Division of Orthopaedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan.

Tomoaki Torigoe (T)

Department of Orthopaedic Oncology and Surgery, Saitama Medical University International Medical Center, Hidaka 350-1298, Japan.

Tomoki Nakamura (T)

Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan.

Hiroya Kondo (H)

Department of Orthopaedic Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University, Okayama 700-8558, Japan.

Toru Wakamatsu (T)

Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka 541-8567, Japan.

Munenori Watanuki (M)

Department of Orthopaedic Surgery, School of Medicine, Tohoku University, Sendai 980-8574, Japan.

Munehisa Kito (M)

Department of Orthopaedic Surgery, School of Medicine, Shinshu University, Matsumoto 390-8621, Japan.

Satoshi Tsukushi (S)

Department of Orthopaedic Surgery, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan.

Akihito Nagano (A)

Department of Orthopaedic Surgery, Gifu University, Gifu 501-1194, Japan.

Hidetatsu Outani (H)

Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan.

Shunichi Toki (S)

Department of Orthopaedics, Institute of Biomedical Sciences, Graduate School, Tokushima University, Tokushima 770-8503, Japan.

Shunji Nishimura (S)

Department of Orthopaedic Surgery, Kindai University Hospital, Osaka-Sayama 589-8511, Japan.

Hiroshi Kobayashi (H)

Department of Orthopaedic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.

Itsuo Watanabe (I)

Department of Orthopaedic Surgery, Tokyo Dental College Ichikawa General Hospital, Ichikawa 272-8513, Japan.

Yusuke Demizu (Y)

Department of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, Kobe 650-0047, Japan.

Ryohei Sasaki (R)

Division of Radiation Oncology, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.

Takumi Fukumoto (T)

Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.

Tomoyuki Matsumoto (T)

Department of Orthopaedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.

Ryosuke Kuorda (R)

Department of Orthopaedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.

Toshihiro Akisue (T)

Department of Orthopaedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe 654-0142, Japan.

Classifications MeSH